Sino Biopharmaceutical HKEx announced that during the six-month period ended June 30, 2022, due to the lower financial performance of an associated company than in the same period last year, the profit attributable to the holders of the group belonging to the parent company decreased by about 78% to about 1.871 billion yuan compared with the same period last year. The profit of the attributable associate decreased during the period, but the Group's main business performance was in line with expectations and the performance grew steadily compared with the same period last year.